Showing 4001-4010 of 7513 results for "".
- Additional Data from Incyte's Phase 3 Studies of Topical Ruxolitinibhttps://practicaldermatology.com/news/additional-data-from-incytes-phase-3-studies-of-topical-ruxolitinib/2460774/Findings from three pooled analyses of Incyte’s randomized, double-blind, vehicle-controlled phase 3 studies evaluating ruxolitinib cream add to previously published data for the investigational topical JAK1/JAK2 inhibitor for atopic dermatitis. Presented at the AAD VMX 2021, new
- Leo Pharma’s Tralokinumab Produces Sustained Improvement in ADhttps://practicaldermatology.com/news/leo-pharmas-tralokinumab-produces-sustained-improvement-in-ad/2460766/Leo Pharma’s tralokinumab 300 mg every other week plus optional topical corticosteroids (TCS) showed long-term improvements in itch, sleep, and in atopic dermatitis signs and symptoms, according to an interim analysis at 56 weeks in the ECZTEND trial that was presented at the AAD
- Biosimilar News: Switching Study Shows Cyltezo and Humira Are Interchangeablehttps://practicaldermatology.com/news/biosimilar-news-switching-study-shows-cyltezo-and-humira-are-interchangeable/2460762/Switching between adalimumab biosimilar Cyltezo and its reference product results in similar pharmacokinetics, efficacy, safety and immunogenicity in people with moderate-to-severe chronic plaque psoriasis, according to new Phase 3 data presented at the American Academy of Dermatology 2021 virtua
- Research Reveals How Skin May Repair Itselfhttps://practicaldermatology.com/news/research-reveals-how-skin-may-repair-itself/2460755/Activation of two transcription factors may enhance a natural process of skin cell division, a desirable outcome in regenerative medicine, according to a study in Nucleic Acid Research. In normal conditions, one in every four cells isolated from the inner layer of the skin
- GEMME Webinar Series to Assess Impact of Essential Mask Wearing on Skinhttps://practicaldermatology.com/news/gemme-webinar-series-to-assess-impact-of-essential-mask-wearing-on-skin/2460754/Assessing the impact of essential mask wearing, the first of a series of four webinars from GEMME (Galderma Excellence Multichannel Medical Education) launches next month. “Under the mask: the consequences of essential mask wearing,” will stream Saturday, May 8, with Drs. Lu
- Yale Cancer Center Study Highlights Novel Immunotherapy Approach to Fight Melanomahttps://practicaldermatology.com/news/yale-cancer-center-study-shows-novel-immunotherapy-approach-to-fight-melanoma/2460748/A tumor-targeting and cell-penetrating antibody can stimulate an immune response to help treat melanoma, Yale researchers reported at the American Association of Cancer Research (AACR) virtual annual meeting. “Most approaches rely on direct injection into tumors of ribonucleic aci
- Arcutis Initiates Phase 3 Clinical Trial of Topical Roflumilast Cream for Pediatric ADhttps://practicaldermatology.com/news/arcutis-initiates-phase-3-clinical-trial-of-topical-roflumilast-cream-for-pediatric-ad/2460743/Arcutis Biotherapeutics, Inc. initiated a pivotal Phase 3 clinical trial evaluating topical roflumilast cream (ARQ-151) as a potential treatment for mild to moderate atopic dermatitis (AD) in patients between the ages of 2 and 5 years old. Roflumilast cream is a once daily topical formulation of
- Pediatric Dermatology Incomes Up; Demand Persists: Surveyhttps://practicaldermatology.com/news/pediatric-dermatology-incomes-up-demand-persists-survey/2460735/Median total compensation for pediatric dermatologists has increased 37 percent since 2014, results of The Society for Pediatric Dermatology’s (SPD) latest compensation report show. The
- Fat Grafting Shows Promise for Cancer Patients with Radiation-induced Skin Injuryhttps://practicaldermatology.com/news/fat-grafting-shows-promise-for-cancer-patients-with-radiation-induced-skin-injury/2460730/As cancer survival rates improve, more people are living with the aftereffects of cancer treatment including chronic radiation-induced skin injury. Fat grafting procedures may unleash the healing and regenerative power of the body's natural adipose stem cells (ASCs). "Prelimina
- Aditxt to Initiate First In-Human Clinical Trials with its Therapeutics Programs in Psoriasishttps://practicaldermatology.com/news/aditxt-to-initiate-first-in-human-clinical-trials-with-its-therapeutics-programs-in-psoriasis/2460724/Aditx Therapeutics, Inc.’s AditxtReprogramming Therapeutics Division is preparing its to begin first-in-human clinical